May 15, 2026 04:05PM
May 15, 2026 04:05PM
May 8, 2026 07:30AM
May 8, 2026 07:30AM
Apr 23, 2026 07:30AM
Apr 23, 2026 07:30AM
Apr 8, 2026 07:30AM Plus Therapeutics receives FDA orphan drug designation for pediatric glioma drug
Apr 8, 2026 07:30AM
Mar 12, 2026 04:15PM
Jan 22, 2026 07:45AM
Jan 22, 2026 07:45AM
Jan 8, 2026 07:31AM
Jan 8, 2026 07:30AM
Nov 26, 2025 07:48AM H.C. Wainwright Reiterates Buy Rating on Plus Therapeutics Inc. (PSTV)
Nov 24, 2025 07:31AM
Nov 24, 2025 07:30AM
Nov 6, 2025 07:30AM
Nov 6, 2025 07:30AM
Oct 30, 2025 04:15PM
Aug 14, 2025 04:15PM
Jul 8, 2025 07:31AM Plus Therapeutics (PSTV) begins treating patients in REYOBIQ dose optimization trial
Jul 8, 2025 07:30AM
Jun 30, 2025 07:30AM
Jun 30, 2025 07:30AM
Jun 26, 2025 07:31AM
Jun 26, 2025 07:30AM
Jun 25, 2025 07:30AM
Jun 25, 2025 07:30AM Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
May 30, 2025 04:15PM
May 14, 2025 07:31AM
May 14, 2025 07:30AM
Apr 15, 2025 07:30AM
Apr 15, 2025 07:30AM
Mar 27, 2025 04:05PM
Mar 20, 2025 07:30AM Plus Therapeutics (PSTV) Introduces REYOBIQ, FDA-Accepted Proprietary Name for Lead Drug Candidate
Mar 20, 2025 07:30AM
Mar 7, 2025 07:30AM
Mar 7, 2025 07:30AM
Mar 6, 2025 07:32AM
Mar 6, 2025 07:30AM
Feb 26, 2025 07:30AM
Feb 26, 2025 07:30AM Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
Feb 24, 2025 07:31AM
Feb 24, 2025 07:30AM
Feb 20, 2025 07:30AM
Feb 20, 2025 07:30AM
Feb 18, 2025 07:30AM
Feb 18, 2025 07:30AM
Dec 17, 2024 07:30AM Plus Therapeutics (PSTV) Presents Positive ReSPECT-LM Phase 1 Interim Data
Dec 17, 2024 07:30AM

323,580 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All